Aardvark Therapeutics (NASDAQ:AARD) Earns “Hold” Rating from Stifel Nicolaus

Aardvark Therapeutics (NASDAQ:AARD)‘s stock had its “hold” rating reiterated by research analysts at Stifel Nicolaus in a research note issued on Monday, Marketbeat.com reports. They presently have a $6.00 target price on the stock, down from their prior target price of $24.00. Stifel Nicolaus’ price objective would suggest a potential upside of 22.45% from the company’s previous close.

Other research analysts have also issued research reports about the stock. Morgan Stanley reaffirmed an “equal weight” rating and issued a $7.00 target price (down from $29.00) on shares of Aardvark Therapeutics in a research note on Monday. B. Riley Financial assumed coverage on Aardvark Therapeutics in a research note on Wednesday, January 28th. They issued a “buy” rating and a $32.00 target price on the stock. Royal Bank Of Canada lowered Aardvark Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $18.00 to $6.00 in a research report on Monday. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $47.00 price target on shares of Aardvark Therapeutics in a research note on Monday, January 12th. Finally, William Blair started coverage on Aardvark Therapeutics in a report on Friday, December 12th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $25.09.

Aardvark Therapeutics Stock Performance

NASDAQ:AARD opened at $4.90 on Monday. The stock’s fifty day moving average price is $13.20 and its two-hundred day moving average price is $12.10. The company has a market cap of $106.67 million and a price-to-earnings ratio of -2.31. Aardvark Therapeutics has a 52-week low of $4.74 and a 52-week high of $17.94.

Insider Activity

In other news, CEO Tien-Li Lee purchased 7,000 shares of Aardvark Therapeutics stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $14.48 per share, with a total value of $101,360.00. Following the transaction, the chief executive officer directly owned 1,551,613 shares in the company, valued at $22,467,356.24. The trade was a 0.45% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Nelson Sun purchased 3,000 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were acquired at an average cost of $14.40 per share, with a total value of $43,200.00. Following the completion of the purchase, the chief financial officer directly owned 108,484 shares in the company, valued at approximately $1,562,169.60. This represents a 2.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Institutional Investors Weigh In On Aardvark Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AARD. Citadel Advisors LLC boosted its stake in shares of Aardvark Therapeutics by 5.9% during the 3rd quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock worth $18,073,000 after buying an additional 76,151 shares during the last quarter. Laurion Capital Management LP boosted its position in Aardvark Therapeutics by 6.1% during the third quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock valued at $13,951,000 after purchasing an additional 60,653 shares during the last quarter. Vanguard Group Inc. grew its stake in Aardvark Therapeutics by 20.6% in the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock valued at $7,386,000 after purchasing an additional 94,744 shares in the last quarter. Millennium Management LLC grew its stake in Aardvark Therapeutics by 51.2% in the fourth quarter. Millennium Management LLC now owns 483,340 shares of the company’s stock valued at $6,344,000 after purchasing an additional 163,717 shares in the last quarter. Finally, SymBiosis Capital Partners LLC acquired a new position in shares of Aardvark Therapeutics during the 4th quarter worth approximately $6,255,000.

Key Stories Impacting Aardvark Therapeutics

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: Some sell‑side firms remain constructive: Oppenheimer kept an “outperform” rating (price target cut to $21) and BTIG retained a “buy” (PT cut to $9) — these provide a potential recovery thesis if clinical issues resolve. Oppenheimer/BTIG Notes
• Neutral Sentiment: Other firms reaffirmed non‑buy stances (Stifel hold, Morgan Stanley equal weight, HC Wainwright neutral) with materially lower price targets, signaling divided analyst views and lower short‑term conviction. Analyst Reaffirmations
• Neutral Sentiment: Short‑interest data in recent reports appears inconsistent (reported zeros/NaN and 0.0 days‑to‑cover). The entries flag potential short interest activity but the published numbers look unreliable — monitor for revised filings.
• Negative Sentiment: Clinical setback: Aardvark voluntarily paused its Phase 3 HERO trial in Prader‑Willi Syndrome after “cardiac observations” were reported — the announcement triggered broad media coverage and is the primary driver of selling pressure while the company reviews the safety data. FierceBiotech: Trial Pause BioSpace: Safety Signals BioPharmaDive: Safety Concerns Investing.com: Market Reaction BioWorld: Data Review
• Negative Sentiment: Investor legal risk: Pomerantz LLP announced an investigation into Aardvark on behalf of shareholders, which can prolong uncertainty and increase downside risk until the company discloses results of its safety review. GlobeNewswire: Pomerantz Investigation

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.